9-Nitrocamptothecin selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-nitrocamptothecin- resistant U937 monocytoid cells

AIDS Research and Human Retroviruses

Volumn 15, Issue 3, 1999, Pages 239-245

  Sadaie, M Reza ^a,d   Doniger, Jay ^a   Hung, Chia Ling ^b   Pantazis, Panayotis ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c BROWN UNIVERSITY   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RUBITECAN; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG RESISTANCE; HIV INFECTIONS; HIV-1; HUMANS; NF-KAPPA B; TUMOR CELLS, CULTURED; U937 CELLS; VIRUS REPLICATION;

EID: 0033023748     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311411     Document Type: Article

References (33)

1. Gupta M, Abdel-Megeed M, Hoki Y, Kohlhagen G, Paull K, and Pommier Y: Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517. Mol Pharmacol 1995;48:658-665.
2. Jardine D, Tachedjian G, Locarnini S, and Birch C: Cellular topoisomerase I activity associated with HIV-1. AIDS Res Hum Retroviruses 1993;9:1245-1250.
3. Pantazis P: Preclinical studies of water-insoluble captothecin congeners: Cytoxicity development of resistance, and combination treatments. Clin Cancer Res 1996;1:1235-1244.
4. Takano H, Kohno K, Matsuo K, Matsuda T, and Kuwano M: DNA topoisomerase-targeting antitumor agents and drug resistance. Anticancer Drugs 1992;3:323-330.
5. Wall ME and Wani MC: Antitumor and topoisomerase I inhibition activity of camptothecin and its analogues. Econ Med Plant Res 1991;5:112-127.
6. Pantazis P, Giovanella BC, and Rothenberg HL: Camptothecins: From Discovery to the Patient. Annals of the New York Academy of Science, New York, 1996.
7. Natelson EA, Giovanella BC, Verschraegen CF, et al.: Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(5)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 1996;803:224-230.
8. Verschraegen CF, Natelson EA, Giovanella BC, et al.: A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998;9:36-44.
9. Moulton S, Pantazis P, Epstein JS, and Sadaie MR: 9-Nitrocamptothecin inhibits tumor-necrosis factor-mediated activation of the human immunodeficiency virus type 1 (HIV-1) and enhances apoptosis in a latently infected T-cell clone. AIDS Res Hum Retroviruses 1998;14:39-49.
10. Kashanchi F, Melpolder JC, Epstein JS, and Sadaie MR: Rapid and sensitive detection of cell-associated HIV-1 in latently infected cell lines and in patient cells using sodium-n-butyrate induction and RT-PCR. J Med Virol 1997;52:179-189.
11. Wahl SM, Orenstein JM, and Smith PD: Immunology of HIV infection (Gupta S, ed.). Plenum Press, New York, 1996, pp. 303-336.
12. Franzoso G, Biswas P, Poli G, et al.: A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. J Exp Med 1994;180:1445-1456.
13. Pantazis P, Mendoza JT, De Jesus A, Rubin E, Kufe D, and Giovanella BC: Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin. Eur J Haematol 1994;53:135-144.
14. Rubin E, Pantazis P, Bharti A, Toppmeyer D, Giovanella B, and Kufe D: Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem 1994;269:2433-2439.
15. Schmidt NJ: Cell culture techniques for diagnostic virology. In: Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections (Lennette EH and Schmidt NJ, eds.). American Public Association, Washington, D.C., 1979, pp. 65-139.
16. Bours V, Burd PR, Brown K, et al.: A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site. Mol Cell Biol 1992;12:685-695.
17. Havlir DV, Eastman S, Gamst A, and Richamn DD: Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. J Virol 1996;70: 7894-7899.
18. Lange JM: Current problems and the future of antiretroviral drug trials. Science 1997;276:548-550.
19. Wong JK, Hezareh M, Gunthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295. [See comments]
20. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
21. Zhang JL, Sharma PL, Li CJ, Dezube BJ, Pardee AB, and Crumpacker CS: Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I. Antimicrob Agents Chemother 1997;41:977-981.
22. Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, and Giovanella BC: Camptothecin derivatives induces regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 1993;53:863-871.
23. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR, and Giovanella BC: Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: Differential responses of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 1993;53:1577-1582.
24. Pantazis P, Early JA, Mendoza JT, De Jesus AR, and Giovanella BC: Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res 1994; 54:771-776.
25. Pourquier P, Ueng LM, Kohlhagen G, et al.: Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem 1997;272:7792-7796.
26. Stehlin JS, Natelson EA, Hinz HR, et al.: Phase I clinical trial and pharmacokinetic results with oral administration of 20(S)-camptothecin. In: Camptothecins: New Anticancer Agents (Potmesil M and Pinedo H, eds.). CRC Press, Boca Raton, Florida, 1995, pp. 59-65.
27. Li CJ, Wang C, and Pardee AB: Camptothecin inhibits Tat-mediated transactivation of type 1 human immunodeficiency virus. J Biol Chem 1994;269:7051-7054.
28. Baichwal VR and Baeuerle PA: Activate NF-kappa B or die? Curr Biol 1997;7:R94-R96.
29. Bargou RC, Emmerich F, Krappmann D, et al.: Constitutive nuclear factor-kappa B-Rel A activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-2969.
30. Wu MX, Ao Z, Prasad KV, Wu R, and Schlossman SF: IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science 1998;281:998-1001.
31. Wang C, Mayo MW, Korneluk MW, Goeddel DV, and Albert SBS, Jr.: NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-1683.
32. Barinaga M: Life-death balance within the cell. Science 1996;274:724.
33. Piret B and Piette J: Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. Nucleic Acids Res 1996;24:4242-4248.